Furthermore, vaccination of mice with the ΔyscN mutant provided some level of protection against a s.c. challenge (the equivalent of ~90LD50) with the wild-type strain for even the group vaccinated with the lowest mutant dose. Following two vaccinations with varying doses of the ΔyscN mutant, quantitative anti-F1 and anti-LcrV ELISA were performed with sera collected from the vaccinated mice. As expected for a yscN mutant, no increase in the immune response to LcrV was determined. Variability in the quantitative anti-F1 ELISA titers as demonstrated by the high standard deviations was reflected somewhat in the flattened survival results and may be

the result of testing only three mice per dosage group. Variation in antibody titers has also been reported by others

using live mutant Y. pestis vaccine strains (Okan et al., 2010; U0126 Oyston et al., 2010). These results may suggest that with this live vaccine strain, anti-F1 titers may not be solely protective and that other bacterial antigens or cytokine-mediated immunity (Kummer et al., 2008) may also play a concerted role in protection. The humoral immune response against Y. pestis is directed against multiple proteins, many encoded by genes on the virulence plasmids (Benner et al., 1999). Among them, the acquired immunity to F1 and LcrV is sufficient to typically protect against plague (Powell et al., 2005). However, the emergence of atypical F1 mutants fully virulent in humans and with natural heterogeneity to Y. pestis LcrV highlights the limits HDAC inhibitor of the current rF1-V fusion vaccine (Quenee et al., 2008). In conclusion, future work with use of the ΔyscN mutant as a live vaccine should proceed. The current study provides initial steps toward this goal. To further characterize the use of this strain as a potential vaccine, many other studies would need to be completed, such as histopathological analysis

of the vaccinated mice. In addition, testing for protection Ibrutinib cost against pneumonic plague would need to be explored. It is not uncommon for mutant strains of Y. pestis to be attenuated in bubonic models but still retain virulence in pneumonic challenges (Friedlander et al., 1995; Welkos et al., 1995, 1997; Worsham & Roy, 2003; Cathelyn et al., 2006; Bozue et al., 2011). We thank Brad Stiles and Susan Welkos for review of this manuscript, and Diane Fisher for completing the statistical analysis of this study. This work was funded by the Defense Threat Reduction Agency (project 2.10019_08_RD_B to W.S.). Research was conducted in compliance with the Animal Welfare Act and other federal statutes and regulations relevant to animals and experiments using animals and complies with all principles stated in the Guide for the Care and Use of Laboratory Animals (National Research Council, 1996). The research facility used is fully accredited by the Association for Assessment and Accreditation of Laboratory Care International.